Quinolone Compound Targeting Clostridium difficile
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infections, such as those caused by antibiotics-associated diarrhea, are limited and often result in relapse, with existing antibiotics like vancomycin and metronidazole showing inefficacies, and there is a need for more effective antimicrobial agents.
Innovation Solution
Development of a novel quinolone compound with excellent antimicrobial activity, specifically designed to target Clostridium difficile, which is administered as a pharmaceutical composition for prevention or treatment of bacterial infections including Clostridium difficile-associated diarrhea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics (vancomycin or metronidazole) are used for Clostridium difficile infection, then treatment can be provided, but relapse occurs frequently and efficacy is limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of quinolone compounds through specific substitutions at positions R1, R2, R3, R4, and R10 with various functional groups (halogens, alkyl groups, heterocyclic groups, etc.). These structural parameter changes result in compounds with enhanced antimicrobial activity against Clostridium difficile while maintaining selectivity, thereby improving treatment efficacy and reducing relapse compared to existing antibiotics.
2Object-affected harmful factors
If antibiotics are used to treat Clostridium difficile infection, then bacterial growth is inhibited, but normal microbial flora of the gut is disrupted
Solution Approach 1:
The patent applies local quality by designing quinolone compounds with specific molecular characteristics that enable selective targeting of Clostridium difficile through its unique cell wall structure and metabolic pathways. The compounds exhibit localized action against C. difficile while sparing other gut flora, achieving effective bacterial inhibition without broad-spectrum disruption of normal microbial flora.
3Reliability
If novel quinolone compounds are developed for Clostridium difficile, then antimicrobial activity is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the quinolone molecule into distinct functional regions (positions R1, R2, R3, R4, R10) that can be independently optimized. Each position can be substituted with specific groups to enhance different aspects of activity (e.g., gram-positive bacteria targeting, metabolic stability, solubility), allowing systematic improvement of antimicrobial activity while managing structural complexity through modular design.
Data Source
Figure 1~2
AI summary
The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile- associated diarrhea.